sildenafil-citrate and Developmental-Disabilities

Fetal growth restriction (FGR) is associated with an increased incidence of fetal and neonatal death, and of neonatal morbidity. Babies born following FGR also are at risk of a range of postnatal complications, which may contribute to an increased incidence of disease later in life. There currently are no effective clinical interventions which improve perinatal survival, intrauterine growth and later outcomes of the FGR baby. Postnatal interventions aimed at promoting or accelerating growth in FGR babies to improve outcome, particularly neurodevelopmental outcomes, may further increase the risk of metabolic dysregulation and, therefore, the risk of developing chronic disease in adulthood. An intrauterine intervention to improve nutrition and growth in the FGR fetus may have the potential to decrease mortality and improve long-term outcomes by delaying preterm delivery and mitigating the need for and risks of accelerated postnatal growth.

Topics: Blood Flow Velocity; Developmental Disabilities; Female; Fetal Development; Fetal Growth Retardation; Fetal Monitoring; Gestational Age; Humans; Insulin-Like Growth Factor I; Maternal Nutritional Physiological Phenomena; Perinatal Care; Placental Circulation; Pregnancy; Premature Birth; Sildenafil Citrate; Uterine Artery; Vasodilator Agents